Last 241.10 INR
Change Today 0.00 / 0.00%
Volume 0.0
JBP On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:25 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

jenburkt pharmaceuticals (JBP) Snapshot

Open
242.00
Previous Close
244.80
Day High
251.00
Day Low
235.00
52 Week High
08/21/14 - 269.50
52 Week Low
10/1/13 - 64.00
Market Cap
1.1B
Average Volume 10 Days
26.6K
EPS TTM
13.37
Shares Outstanding
4.6M
EX-Date
09/3/14
P/E TM
18.0x
Dividend
5.10
Dividend Yield
1.74%
Current Stock Chart for JENBURKT PHARMACEUTICALS (JBP)

Related News

No related news articles were found.

jenburkt pharmaceuticals (JBP) Related Businessweek News

No Related Businessweek News Found

jenburkt pharmaceuticals (JBP) Details

Jenburkt Pharmaceuticals Ltd manufactures and markets pharmaceutical formulations and healthcare products in India. Its Consumer division provides Nocal tablets, Nocal sachets, and Nocal granular products. The company’s Pharmaceutical division offers various products in the areas of anti-arthritic, anti-osteoporotic, antibiotic, anti-diabetic, neuropathy, anti-inflammatory analgesic, gastro intestinal, dermatological, aphrodisiac, anti-ulcerant drugs, anti-malerial, anti-hypertensive, anthelmintics, hematinics, and protein preparation, as well as anti-cough, cold, and allergy. It also exports its products to Asian and African countries. Jenburkt Pharmaceuticals Ltd serves doctors, chemist, and retailers, as well as large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. The company promotes approximately 45 brands through doctors, as well as through medical representatives internationally. Jenburkt Pharmaceuticals Ltd was founded in 1985 and is headquartered in Mumbai, India.

Founded in 1985

jenburkt pharmaceuticals (JBP) Top Compensated Officers

Chairman and Managing Director
Total Annual Compensation: 7.8M
Whole-Time Director
Total Annual Compensation: 1.3M
Compensation as of Fiscal Year 2014.

jenburkt pharmaceuticals (JBP) Key Developments

Jenburkt Pharmaceuticals Ltd. Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2014

Jenburkt Pharmaceuticals Ltd. reported unaudited standalone earnings results for the first quarter ended June 30, 2014. For the quarter, the company's net sales/income from operations was INR 192.093 million compared with INR 170.355 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 21.385 million compared with INR 18.770 million a year ago. Profit from ordinary activities before tax was INR 20.882 million compared with INR 13.860 million a year ago. Net profit was INR 14.882 million or INR 3.20 per basic and diluted share compared with INR 9.360 million or INR 2.01 per basic and diluted share a year ago.

Jenburkt Pharmaceuticals Ltd., Board Meeting, Jul 28, 2014

Jenburkt Pharmaceuticals Ltd., Board Meeting, Jul 28, 2014. Agenda: To consider quarterly results.

Jenburkt Pharmaceuticals Ltd. Recommends Dividend

Jenburkt Pharmaceuticals Ltd. recommended a dividend of INR 5.10 (51%) per equity share of INR 10 each.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JBP:IN 241.10 INR 0.00

JBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JBP.
View Industry Companies
 

Industry Analysis

JBP

Industry Average

Valuation JBP Industry Range
Price/Earnings 13.6x
Price/Sales 1.4x
Price/Book 4.0x
Price/Cash Flow 11.4x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JENBURKT PHARMACEUTICALS, please visit www.jenburkt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.